Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE)
- PMID: 34847156
- PMCID: PMC8631660
- DOI: 10.1371/journal.pone.0260320
Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE)
Abstract
The screening for undiagnosed non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (SUNN) study was a population-based screening study that aimed to provide proof of concept to encourage community-level screening and detection for this non-communicable disease. Current screening guidelines do not recommend the routine screening of nonalcoholic fatty liver disease (NAFLD) for asymptomatic populations, so providers are not encouraged to actively seek disease, even in high-risk patients. This study sought to determine whether a self-selecting cohort of asymptomatic individuals would have scores based on vibration controlled transient elastography (VCTE) and controlled attenuation parameter (CAP) significantly correlated to risk factors to suggest that routine screening for high-risk patients should be recommended. The study recruited 1,070 self-selected participants in Houston and Galveston County, Texas, 940 of which were included in final analysis. A pre-screening survey was used to determine eligibility. VCTE-based scores analyzed steatosis and fibrosis levels. Fifty-seven percent of the study population demonstrated steatosis without fibrosis, suggesting NAFLD, while 16% demonstrated both steatosis and fibrosis, suggesting NASH. Statistically significant risk factors included factors related to metabolic syndrome, race, and age, while statistically significant protective factors included consumption of certain foods and exercise. The findings of this study suggest that high-risk individuals should be screened for NAFLD even in the absence of symptoms and that community-based screenings are an effective tool, particularly in the absence of proactive guidelines for providers.
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests: WE, GAW, MLH, and HEC are employees of FLF, which reports program support and educational grants from Allergan, Amazon, Bristol-Myers Squibb, Celgene, Clinical Care Options, Continuum Clinical, Echosens, Eskridge Family Trust, Fibronostics, First Line Creative, Gilead Sciences, Global Engage, Google, Health Business Solutions, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Meetrix, Merck & Co., Inc. NetNoggin, Prosciento, Pfizer, Terns Pharmaceuticals and various private and philanthropic individual donors. JMV reports relevant research and grant support from Allergan, Alnylam, 89Bio, Bristol-Myers Squibb, Celgene, CymaBay, Exalenz, Galectin, Galmed, Genfit, Gilead, Hanmi, Immuron, Intercept, Madrigal, Merck, Mochida, Molecular Stethoscope, Novartis, NovoNordisk, Pliant, Sagimet, Tobira Therapeutics, and Zydus; advisor or consultant fees from Allergan, Blade Pharmaceuticals, Bristol-Myers Squibb, Conatus, CymaBay, Exalenz, Fractyl, Intercept, Novartis; and is on the Data Safety and Management Boards for NIH NIDDK Drug-Induced Liver Injury Network (DILIN) and Fractyl. WG reports grant support from AbbVie and Gilead Sciences. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Figures
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
